Ammar, Usama M. Abdel-Maksoud, Mohammed S. Oh, Chang-Hyun 2024-01-19T21:33:07Z 2024-01-19T21:33:07Z 2022-01-10 2018-10-05 0223-5234 https://pubs.kist.re.kr/handle/201004/120800 Frequent oncogenic mutations have been identified in MAPK (mitogen-activated protein kinase) signaling pathway components. As a result, MAPK pathway is associated with human cancer initiation, in particular RAF (rapidly accelerated fibrosarcoma) component. The mutation in RAF component leads to auto-activation of MAPK signaling pathway, stimulating the uncontrolled cell growth and proliferation. In last few years, diverse chemical scaffolds have been identified as RAF inhibitors. Most of these scaffolds show potent anti-cancer activity. The present review highlights the recent investigations of RAF inhibitors during the last five years. (C) 2018 Published by Elsevier Masson SAS. English ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER LUNG-CANCER CELLS ACTIVATED PROTEIN-KINASE SPECTRUM ANTIPROLIFERATIVE ACTIVITY POTENTIAL ANTITUMOR AGENTS DIARYL UREA DERIVATIVES BRAF V600E MUTATION B-RAF BIOLOGICAL EVALUATION PYRAZOLINE DERIVATIVES PHARMACOPHORE APPROACH Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents Article 10.1016/j.ejmech.2018.09.005 1 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, v.158, pp.144 - 166 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 158 144 166 scie scopus 000448094000012 2-s2.0-85053076819 Chemistry, Medicinal Pharmacology & Pharmacy Review LUNG-CANCER CELLS ACTIVATED PROTEIN-KINASE SPECTRUM ANTIPROLIFERATIVE ACTIVITY POTENTIAL ANTITUMOR AGENTS DIARYL UREA DERIVATIVES BRAF V600E MUTATION B-RAF BIOLOGICAL EVALUATION PYRAZOLINE DERIVATIVES PHARMACOPHORE APPROACH MAPK RAF inhibitors Anti-cancer agents